Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, 2-regimen, Repeat-dose Study to Assess the Safety and Pharmacokinetics of Intravenous CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis

NCT03972280 is registered in ClinicalTrials.gov with CSL Behring as lead sponsor.

NCT NCT03972280
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03972280 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, 2-regimen, Repeat-dose Study to Assess the Safety and Pharmacokinetics of Intravenous CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis
Lead sponsor
CSL Behring
Phase
Phase 1
Overall status
Completed
Start date
July 4, 2019
Completion date
October 4, 2022
Enrollment
39 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa, palmoplantar pustulosis